Inventiva S.A. (IVA) Stock

About Inventiva S.A.

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

Inventiva S.A. is headquartered in FR.

Inventiva S.A. (IVA) stock trades at $4.47 with a market capitalization of $232.36M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.04, reflecting a net loss over the last twelve months, a negative price-to-book of -86.44, reflecting negative shareholders' equity, price-to-sales of 120.05. Over the past 52 weeks the stock has ranged between $2.85 and $7.98, and currently trades 44.0% below its 52-week high.

On profitability, Inventiva S.A. generates a return on equity (ROE) of 1172.41% (not meaningful, as shareholders' equity is negative), return on capital employed of -79.10%, an operating margin of -3275.00%, a net profit margin of -8500.00%.

Official website: www.inventivapharma.com

Inventiva S.A. by the numbers, 2016–2025

Between 2016 and 2025 Inventiva S.A. reported revenue of $9.0M rising to $4.0M, a change of -55.6% across 10 years. Compounded, revenue has grown —% a year over five years, -30.7% over three, -55.6% over the last twelve months. Net profit fell to $-340.0M.

Operating margin went from -137.8% in 2016 to -2921.0% in 2025, a fall of 2783.1 percentage points. The most recent net margin is -8500.00%. On a trailing twelve-month basis to Dec '25, revenue is $13.0M and net profit $-537.0M.

Borrowings rose from $1.0M to $59.0M, cash on hand is $99.3M, cash from operations was $-101.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 302.4% over five years, and was 1172.4% in the most recent year.

The share price itself has compounded at -20.8% a year over five years, 1.6% over three, 34.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Inventiva S.A. (IVA) — frequently asked questions